Artelo Biosciences Announces Pricing of $8.0 Million Public Offering and Uplisting to Nasdaq

LA JOLLA, Calif., June 21, 2019 (GLOBE NEWSWIRE) — Artelo Biosciences, Inc. (NasdaqCM: ARTL, ARTLW) (the ?Company? or ?Artelo Biosciences?), a clinical-stage biopharmaceutical company with a portfolio of novel therapeutic candidates targeting the endocannabinoid system, today announced the pricing of its public offering of 1,300,813 units at a price to the public of $6.15 per unit.? Each unit issued in the offering consists of one share of common stock and one warrant to purchase one share of common stock at an exercise price of $6.4575 per share. No units will be issued.? The common stock and warrants are immediately separable from the units and will be issued separately. The common stock and warrants are expected to begin trading on the Nasdaq Capital Market on June 21, 2019, under the symbols ?ARTL? and ?ARTLW,? respectively. Artelo Biosciences expects to receive gross proceeds of $8.0 million, before deducting underwriting discounts and commissions and other e